| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| Other Sizes |
|
Purity: ≥98%
7ACC2 (7-ACC2), an aminocarboxycoumarin derivative, is a novel and potent MCT (Monocarboxylate transporters) inhibitor with anticancer activity. It inhibits MCT with IC50 of 11 nM for inhibition of [14C]-lactate influx; Compare with warfarin, a conventional anticoagulant coumarin, 7ACC2 did not influence the prothrombin time which, together with a good in vitro ADME profile, supports the potential of this new family of compounds to act as anticancer drugs through inhibition of lactate flux. Under hypoxia, cancer cells consume glucose and release lactate at a high rate. Lactate was recently documented to be recaptured by oxygenated cancer cells to fuel the TCA cycle and thereby to support tumor growth. Monocarboxylate transporters (MCT) are the main lactate carriers and therefore represent potential therapeutic targets to limit cancer progression.
| ln Vitro |
Compound 19 (7ACC2), which suppresses SiHa cell proliferation in lactate-containing media, has an EC50 of 0.22 μM. It works for 72 hours. The high affinity MCT1 transporter is the main factor influencing lactate uptake in SiHa cells[1]. Compound 19, or 7ACC2, exhibits remarkable chemical stability in simulated gastric (SGF) and intestinal (SIF) fluids, a good apparent permeability coefficient (Papp) through the Caco-2 monolayer, and a high level of metabolic stability on human hepatocytes, mouse liver microsomes, and human liver microsomes [1]. 7ACC2 is a strong inhibitor of mitochondrial pyruvate transport that increases intracellular pyruvate buildup, hence blocking the uptake of extracellular lactate[2].
|
|---|---|
| ln Vivo |
Treatment with 7ACC2 (3 mg/kg; intraperitoneal administration; daily; for 5 days or 10 days) dramatically reduces the growth of tumors in mice. 7ACC2 decreases hypoxia in vivo, which radiosensitizes tumor cells[2]. When mice are given 7ACC2 (compound 19; 3 mg/kg) intraperitoneally, they quickly reach a Cmax of 1246 ng/ml (4 μM) (Tmax=10 min), which is accompanied by a 4.5-hour plasma half-life[1].
|
| Animal Protocol |
Animal/Disease Models: 7-week- old female NMRI nude mice with radiotherapy administered[2]
Doses: 3 mg/kg Route of Administration: intraperitoneal (ip)administration; daily; for 5 days or 10days Experimental Results: A significant increase in tumor growth delay was observed. |
| References |
|
| Molecular Formula |
C18H15NO4
|
|
|---|---|---|
| Molecular Weight |
309.32
|
|
| Exact Mass |
309.1
|
|
| Elemental Analysis |
C, 69.89; H, 4.89; N, 4.53; O, 20.69
|
|
| CAS # |
1472624-85-3
|
|
| Related CAS # |
|
|
| PubChem CID |
72696735
|
|
| Appearance |
Light yellow to yellow solid powder
|
|
| Density |
1.4±0.1 g/cm3
|
|
| Boiling Point |
548.9±50.0 °C at 760 mmHg
|
|
| Flash Point |
285.8±30.1 °C
|
|
| Vapour Pressure |
0.0±1.6 mmHg at 25°C
|
|
| Index of Refraction |
1.672
|
|
| LogP |
4.17
|
|
| Hydrogen Bond Donor Count |
1
|
|
| Hydrogen Bond Acceptor Count |
5
|
|
| Rotatable Bond Count |
4
|
|
| Heavy Atom Count |
23
|
|
| Complexity |
495
|
|
| Defined Atom Stereocenter Count |
0
|
|
| SMILES |
O1C(C(C(=O)O[H])=C([H])C2C([H])=C([H])C(=C([H])C1=2)N(C([H])([H])[H])C([H])([H])C1C([H])=C([H])C([H])=C([H])C=1[H])=O
|
|
| InChi Key |
XTKDQPFUOFAMRL-UHFFFAOYSA-N
|
|
| InChi Code |
InChI=1S/C18H15NO4/c1-19(11-12-5-3-2-4-6-12)14-8-7-13-9-15(17(20)21)18(22)23-16(13)10-14/h2-10H,11H2,1H3,(H,20,21)
|
|
| Chemical Name |
7-[benzyl(methyl)amino]-2-oxochromene-3-carboxylic acid
|
|
| Synonyms |
|
|
| HS Tariff Code |
2934.99.9001
|
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
|
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
|
|||
|---|---|---|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 2.5 mg/mL (8.08 mM) in 10% DMSO + 40% PEG300 +5% Tween-80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), suspension solution; with sonication.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 + to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.2329 mL | 16.1645 mL | 32.3290 mL | |
| 5 mM | 0.6466 mL | 3.2329 mL | 6.4658 mL | |
| 10 mM | 0.3233 mL | 1.6164 mL | 3.2329 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA